Q4 2016

Latest Quarterly Results
Ended June 30, 2016


Research and development YTD


Net cash used in operations YTD

Company Profile

Propanc is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ proenzymes, which are inactive precursors of enzymes.

Frequently Asked Questions

Answers to commonly asked questions

View FAQ

IR Contact Information

Investor Relations

KCSA Strategic Communications
Philip Carlson
880 Third Ave
6th Floor
New York, NY 10022
T: 212-896-1233

Transfer Agent

Corporate Stock Transfer Inc.
3200 Cherry Creek South Drive
Suite 430
Denver, CO 80209
T: 303-282-4800